Dyax adds new Asian deal for Kalbitor to CVie
This article was originally published in Scrip
Executive Summary
Dyax Corp has been seeking new partnerships to grow its mainstay product Kalbitor (ecallantide) since a setback for the plasma kallikrein inhibitor in Europe in late 2011, when the US firm withdrew a marketing authorization application after regulators deemed the data insufficient to demonstrate a positive risk-benefit balance.